Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19107


This phase I trial studies the side effects and best dose of bendamustine hydrochloride in treating patients with previously treated multiple myeloma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study summary:

PRIMARY OBJECTIVES: I. To identify a maximum tolerated dose of bendamustine (bendamustine hydrochloride) in patients with multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the safety of escalating doses of bendamustine in patients with multiple myeloma. II. To describe the response after bendamustine OUTLINE: This is a dose-escalation study. Patients receive bendamustine hydrochloride intravenously (IV) over 60-180 minutes on days 1 and 2.


Inclusion Criteria: 1. Patients with multiple myeloma who have not achieved a CR following at least 4 cycles of induction therapy 2. Age up to 80 years 3. ECOG Performance Status of 0 or 1 4. Left ventricular ejection fraction =/> 40%. No uncontrolled arrhythmias or symptomatic cardiac disease 5. FEV1, FVC and DLCO =/> 40%. No symptomatic pulmonary disease. 6. Serum bilirubin <2 x upper limit of normal, alkaline phosphatase <3 x upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites > 1 L prior to drainage. 7. HIV negative 8. Negative beta HCG test in woman with child bearing potential, defined as not post-menopausal for 12 months or no previous sterilization 9. Patients or guardian able to sign informed consent 10. Availability of previously collected autologous stem cells (at least 3.0 x 106 CD34 cells/kg) 11. Calculated GFR > 50 ml/minute Exclusion Criteria: 1. Patients with uncontrolled hypertension (systolic > 140, diastolic > 90 despite antihypertensive therapy 2. Patients with uncontrolled bacteria, viral or fungal infections (currently taking medication and progression of clinical symptoms) 3. New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities 4. Relapsed/refractory myeloma



Primary Contact:

Principal Investigator
Manish Sharma, MD
Thomas Jefferson University

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19107
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.